GlassScriptPhysician profile
Natasha Dudiki
NPI 1366859142
$4,574.51
in general payments reported to CMS, 2019-2025
17 companies · $2,027 in 2025
The $2,027 reported for 2025 was more than what 87% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $135 · 2022: $516 · 2023: $390 · 2024: $1,506 · 2025: $2,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,116 · Food and Beverage: $1,790 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,116.39 |
| Food and Beverage | $1,789.62 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,387.24 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $840.57 | 2022-2025 | Tezspire, Fasenra, Symbicort |
| Glaxosmithkline, LLC. | $684.11 | 2021-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.48 | 2021 | |
| Merck Sharp & Dohme LLC | $116.10 | 2024-2025 | Zerbaxa, Dificid, Recarbrio |
| Regeneron Healthcare Solutions, INC. | $87.16 | 2023-2025 | Dupixent |
| Mylan Specialty L.P. | $75.28 | 2022-2024 | Yupelri |
| Viatris Specialty LLC | $52.82 | 2025 | Yupelri |
| Amgen INC. | $45.31 | 2022-2025 | Tezspire |
| Pfizer INC. | $40.29 | 2024-2025 | |
| Philips North America LLC | $33.31 | 2022 | |
| United Therapeutics Corporation | $24.87 | 2024 | Tyvaso |
| Mallinckrodt Hospital Products INC. | $17.78 | 2023 | Acthar |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Janssen Pharmaceuticals, INC | $15.49 | 2023 | Xarelto |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $13.32 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natasha Dudiki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.